It is well known that the KIT oncogene inhibitor imatinib has been widely used in clinical practice and has been approved for use in melanoma, gastrointestinal stromal tumor (GIST), and chronic myelogenous leukemia (CML) patients with KIT mutations [18,19]. Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.